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ABSTRACT: Computational chemists typically assay drug candidates by virtually screening 
compounds against crystal structures of a protein despite the fact that some targets, like the µ 
Opioid Receptor and other members of the GPCR family, traverse many non-crystallographic 
states. We discover new conformational states of µOR with molecular dynamics simulation and 
then machine learn ligand-structure relationships to predict opioid ligand function. These 
artificial intelligence models identified a novel µ opioid chemotype. 
 
 
  
Introduction and Methodological Advance 
 
A single class of proteins, the G-Protein Coupled Receptors (GPCRs), comprises over one-third 
of the targets of all FDA-approved drugs1. One such GPCR, the µ Opioid Receptor (µOR), 
epitomizes the benefits and drawbacks of existing GPCR drugs. Opioid chronic pain 
medications, such as morphine and hydrocodone, are µOR agonists that achieve their main 
therapeutic aim of analgesia, yet cause severe side effects, such as respiratory depression and 
addiction2. 
 
Like other GPCRs, µOR is not a binary switch. Rather, biophysical experiments indicate that 
GPCRs in general3,4 and µOR in particular5–9 traverse a spectrum of conformational states.  
Our central thesis is that µOR samples a multiplicity of functionally relevant and 
pharmacologically predictive states.  We have tested this hypothesis by developing novel 
computational methods to identify and incorporate these states, both yielding an increased AUC 
in opiate activity prediction and empowering the discovery of new opioid scaffolds.  
Specifically, we posit that identifying important µOR states beyond the two crystal structures10,11 
would improve the ability to predict the activity of ligands at the Receptor.  
 
To test this hypothesis, we conducted long timescale MD simulations of µOR either unliganded or 
bound to one of several agonists: BU7212, Sufentanil13, TRV13014, and IBNtxA7, providing a 
heterogeneous yet comprehensive spectrum of conformations that µOR can adopt. This dataset 
expands upon previous works15,16 which focus on the conformational dynamics of the receptor. To 
systematically process such a large parallel MD dataset, consisting of an unprecedented 1.1 
milliseconds of µOR simulation, we apply a kinetically motivated machine learning approach that 
(1) identified the reaction coordinates of µOR using the cutting-edge Sparse tICA algorithm17–19 
and (2) defined discrete receptor states using Minibatch K-Means clustering20.  
This unsupervised step uncovered key conformations of µOR, consisting both of intermediates 
between as well as non-canonical states distinct from the crystal structures (Figure 1, ref.15). In 
light of recent studies21,22, these structures are potentially druggable states that can be directly 
employed to enrich rational drug discovery campaigns for µOR. To realize this potential, we 
trained supervised machine learning models that demonstrate significant improvement in two 
binary classifier tasks (Table 1): (1) the ability to distinguish agonists from antagonists, and (2) 
the ability to distinguish binders from non-binders at µOR. 
 
Specifically, random forests23, an increasingly prevalent machine learning tool in drug design, 
were deployed to connect structure to function. A database of opioids with known 
pharmacologies was docked to both the crystal structures as well as to a representative 
conformation of each state. The docking scores of each ligand to each MD conformation were 
then used as the input (E.D. Fig. 3), or feature matrix, to binary classifier24 models for both 
agonism and binding at µOR. 
 
Statistical Results and Small Molecule Discovery 
 
This dually unsupervised and supervised ML-based synthesis of structural information from both 
crystallography and MD yielded statistically significant enrichment in both tasks. Model 
performance is evaluated using the Receiver Operating Characteristic (ROC) Area Under the 
Curve (AUC24) and stratified cross-validation (Methods). Cross-validation is a pseudo-
prospective validation of the model which estimates the experimental performance on previously 
unseen query ligands. The new method – which incorporates docking to the MD states in 
addition to the crystal structures – achieved a median AUC improvement of 0.11 in agonism and 
of 0.15 in binding compared to the crystal structures alone (Table 1, E.D. Tables 4 and 5). 
 
In contrast to many previous virtual screening approaches, which are predicated solely on ligand-
derived features, the machine-learning approach described here is based on the affinities of a 
given ligand toward each µOR conformation. As a further test of this method’s robustness to 
agonism, scaffold splits were employed. Specifically, a series of models were trained in which 
analogs of either methadone or fentanyl were removed from the training data and placed in a 
held-out test set (Table 1, E.D. Tables 2 and 4). In other words, none of these models had any a 
priori knowledge of methadone (or, alternately, fentanyl) analogs. Nevertheless, the models 
successfully distinguished both methadone- and fentanyl-derived agonists from random sets of 
antagonists. Analogous scaffold splits were defined for the binding prediction task, yielding 
comparable gains in AUC (Table 1, E.D. Table 5). Therefore, since this method does not 
explicitly incorporate the chemical makeup of the ligand, it is in principle better equipped to 
discover new opioid-active scaffolds in addition to derivatives of existing ones. 
 
In practice this method identified several novel opioid-active ligands that were verified 
experimentally. First, 133,564 small molecules from the Stanford Compound Library were 
docked to both crystal structures and the computationally modeled conformers of µOR. This step 
yielded a 133,564 row by 27 column feature matrix, where entry (i, j) is the docking score of the 
i'th ligand to the j’th conformational state. The two trained random forest models for binding and 
agonism were applied to each library ligand, yielding a final score computed from the product of 
the two values: 
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Both model performance and scaffolds of hits are highly sensitive to the pIC50 cutoff chosen for 
binary classifiers (E.D. Table 5). While models with a lower affinity threshold for binding 
generally have higher AUC, their top hits are more biased toward compounds with a tertiary, 
basic nitrogen similar to known scaffolds. Therefore, we used random forests models with a 
pIC50 cutoff of 8.0 (10 nM) to optimize for novel scaffold discovery. 
 
The thirty highest scoring, immediately purchasable compounds were then experimentally 
assayed. At least three of the thirty compounds exhibited micromolar affinity for µOR (E.D. 
Figure 4, E.D. Table 6). FMP4, because of its unique structure – namely, no basic amine or 
phenol  – was characterized further in binding assays in opioid transfected cell lines. FMP4 had 
3217±153 nM, 2503± 523 nM and 8143±1398 nM affinity at MOR-1, KOR-1 and DOR-1 
respectively (E.D. Figure 5). FMP 4 was also a weak MOR-1 partial agonist in [35S]GTPγS 
functional assays. (E.D. Figure 6). Structurally similar FMP4-like compounds in the same data 
set were also characterized in binding assays and at least two compounds (FMP1 and FMP16) 
showed <10µM affinity at MOR-1 (E.D. Table 7). Structure-activity studies using classical 
medicinal chemistry approaches using these templates as a starting point may lead to compounds 
with higher affinities at the receptor.  
 
Based on these results, opioid prediction is enriched by incorporating conformational states that 
are unforeseeable from crystallography alone and stabilized by ligands in simulation. Notably, 
FMP4 is distinct from known opioid agonists and antagonists, with a maximum Tanimoto score 
of 0.44 to the ligands listed in E.D. Table 1. Underscoring its difference is FMP4’s lack of a 
basic tertiary amine and phenol, that are the hallmark of synthetic opioids, from classic to current 
experimental molecules5,7,14,25. 
 
Modeling predicts that FMP4 binds to and facilitates activation of µOR in a unique way. In 
particular, FMP4 has a relatively high docking score for MD State 3, calculated to be important 
for agonism and binding (E.D. Table 3). Note that tIC.1, the slowest tICA reaction coordinate, 
connects the two crystallographic states (Figure 1). In contrast, tIC.2, the second slowest tICA 
coordinate, is kinetically orthogonal to tIC.1 and defines several non-crystallographic states 
(Figure 1b). Measured by its progress along tIC.1 and by traditional metrics of GPCR 
literature26,27 such as outward orientation of transmembrane helix 6 and bulged configuration of 
the NPxxY motif residues N3327.48-Y3367.53, MD State 3 is a novel active-like state of µOR. 
Near the orthosteric binding site, State 3 entails a rearrangement of Q1242.60, M1513.36, H2976.52, 
Y2996.54, and W3186.35. The new positions of M1513.36 and H2976.52 enable FMP4 to occupy a 
pose that would be sterically forbidden in the active crystal structure (Figure 1a). In contrast to 
the co-crystallized agonist, FMP4 engages in a π-T interaction with W2936.48, a residue critical in 
gating µOR activation10, and a hydrogen bond with H2976.52. A PyMOL session and PDB files of 
each modeled µOR conformation is available in the Extended Data section, and further 
visualizations in E.D. Figure 1. 
 
Discussion  
 
Put together, by enumerating the state space of µOR, one can query conformations of the 
receptor to motivate rational design with all-atom structural information. An ineluctable flood 
of data stems from MD, and it is a significant data science challenge to derive actionable 
knowledge from a vast dataset of simulation alone. One millisecond of MD saved at one frame 
per nanosecond would contain one million conformations, far too many to be viewed by expert 
eyes. Rather, by pursuing a kinetically-motivated statistical approach, it was possible to discover 
key conformations of the receptor within a tractable scope. 
 
A key element of this approach is the estimation of the affinity of each ligand for each of several 
conformations of a receptor. These conformations are obtained in a single MD simulation pre-
step and span a structural basis set for the receptor’s functionality. In contrast, induced fit 
docking28–30 samples different conformations to estimate a single docking (affinity) score for the 
protein. However, its conformational sampling is spatiotemporally limited, extends only to the 
binding pocket, must be repeated for each ligand, and, by outputting a single number correlated 
with affinity it is intrinsically not targeted for predicting agonism.  
 
The method described herein assists translational researchers in realizing a challenging goal: 
identifying novel GPCR drug scaffolds. Despite immense efforts in medicinal chemistry on 
synthesizing derivatives of existing chemotypes, all FDA-approved opioids are riddled with 
serious side effects that restrict their utility in treating acute and chronic pain. In this work, we 
describe a method to leverage crystallography and molecular modeling with machine learning to 
explore previously uncharted chemical space of molecules active at µOR. This approach is 
naturally applicable to any receptor which is expected to have any sort of conformational 
plasticity, including other GPCRs31, kinases, ion channels, and nuclear receptors. The ultimate 
goal of superior opiate therapeutics remains in the future, but now may loom much closer on the 
horizon.  
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Figure 1: a) Active crystal structure (PDB: 5C1M) in green; MD State 3 in dark blue; docked pose of FMP4 to MD State 3 in cyan. Solid 
arrows represent changes in MD from crystal structures. Dashed lines indicate non-covalent interactions between FMP4 and µOR binding 
pocket residues. Note that FMP4 would sterically clash with residues M151 and H297 in the active crystal, possibly accounting for its very 
low docking score to that structure. Movements of M151 and H297 enable favorable noncovalent ligand-protein interactions in a non-
strained conformation of the ligand. Unlike the morphinan phenol, FMP4’s phenyl ring engages with key activation residue W293 with a π-
T aromatic interaction. b) Free energy landscape of µOR projected onto its two slowest collective degrees of freedom. Whereas tICA
coordinate 1 separates the active and inactive (PDB: 4DKL) crystal structures, tICA coordinate 2 is an orthogonal degree of freedom 
defining several non-crystallographic inactive and active-like states. Such states include State 3, critical for FMP4’s ability to engage with 
the receptor. 
a) b)
∆G
Task Split Type AUC (Crystals alone)
AUC (Crystal + MD 
structures)
Agonism Random 0.73 0.85
Agonism Scaffold (Fentanyl) 0.81 0.91
Agonism Scaffold (Methadone) 0.89 0.94
Binding Random 0.64 0.79
Binding Scaffold 0.64 0.78
Table 1: Docking to both MD and crystal structures statistically 
significantly improves ability over crystal structures alone to 
distinguish µOR agonists from antagonists and µOR binders from 
non-binders. Table shows median ROC Area Under the Curve (AUC) 
performance over 1,000 train-validation splits. When either fentanyl 
or methadone analogs are removed from the training set (scaffold 
splits, cf. Methods), models remain able to distinguish fentanyl (or 
methadone) derivative agonists from antagonists. Similarly, when 
ligands with a Tanimoto similarity score greater than 0.7 to any other 
ligand in the database are removed from the training data (scaffold 
split), AUC improves commensurately when building a model 
incorporating MD-derived conformers. Therefore, models fit in this 
way have, in principle, the capacity to discover new opioid scaffolds 
in addition to derivatives of existing ones.
Scheme 1: Compound FMP4 (Pubchem ID: 
2057658) is one of at least four purchased 
compounds with affinity for µOR at least at the 
10 µM level. FMP4 specifically exhibits 3.2 µM 
affinity with weak partial agonism as well.  
 
Figure 2: Method Overview 
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Extended Data and Tables 
 
 
 
 
 
Extended Data Figure 1 
 
Binding pocket views of the top three most important conformational states of µOR derived from MD simulation by 
measure of largest mean reduction in Gini impurity for random forest models of binding and of agonism. A PyMOL 
session as well as individual PDB files of each conformation can be downloaded in the supplemental information 
section.  
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Extended Data Figure 2 
 
Violin plots comparing the two methods’ (docking to crystal structures alone versus docking to crystal structures 
and MSM states) AUC performance over 1000 random train-test splits.  
 
 
 
 
 
  
 
 
Extended Data Figure 3 
 
Visualization of a subset of the feature matrix (X matrix), the input to the machine learning algorithm. Each row is 
an opioid ligand, each column is a feature (docking scores to each of MD States 0-24 and to each crystal structure). 
Therefore, entry (i, j) in the matrix is the docking score of the i'th ligand to the j’th conformational state. For 
visualization, each row is normalized to mean zero and unit variance. Also for visualization, Rows (ligands) and 
columns (features) are also hierarchically clustered.  
 
 
 
 
 
 
 
 
  
 
 
 
Extended Data Figure 4. Screening of MOR-1 binders: Inhibition of 125IBNtxA specific 
binding at MOR-1 was carried out at a single dose 10 µM concentration. Three 
compounds  FMP1, 4 and 16 (circled) showed ≥30% inhibition of MOR-1 binding (red 
dotted line represents compounds showing≥30% inhibition). Each panel is a 
representative experiment that has been independently replicated at least three times. 
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Extended Data Figure 5. Competition assays at MOR-1, KOR-1 and DOR-1 against 
FMP4. Competition studies were performed with FMP4 against 125I-IBNtxA (0.1 nM) in 
membranes from CHO cells stably expressing the indicated cloned mouse opioid 
receptors Each figure is a representative experiment that has been independently 
replicated at least three times. Error bars represent the SEM of triplicate samples. Error 
bars that cannot be seen are smaller than the size of the symbol. FMP4 had 3217±153 
nM, 2503± 523 nM and 8143±1398 nM affinity at MOR-1, KOR-1 and DOR-1 respectively. 
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Extended Figure Data 6:  FMP4 is a partial agonist in [35S]-GTPγS assays in MOR-1 
expressing CHO cells. Results are pooled from 3 independent replications and are 
expressed as mean ± SEM. FMP4 stimulates GTPγS binding at doses 1, 10 and 30 µM 
respectively and shows a ceiling effect consistent with partial agonism at the receptor in 
comparison to the prototypic full MOR-1 agonist DAMGO at 100 nM (one-way ANOVA 
followed by Tukeys post hoc comparisons test, *significantly different from control (p < 
0.0001)).  FMP4 at a dose of 30 µM also antagonized the GTPγS stimulation of 100 nM 
DAMGO consistent with its partial agonism at the receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Simulation Ligand Aggregate MD Simulation, 
Generation 1 
Aggregate MD 
Simulation, 
Generation 2 
Total Number of 
Trajectories 
Apo 115.839 µs 119.620 µs 512 
BU72 102.705 µs 145.794 µs 512 
Sufentanil 105.298 µs 166.723 µs 754 
IBNtxA 93.491 µs 0 µs 256 
TRV130 241.360 µs 0 µs 512 
  1.090830 ms total 2,546 
 
 
Extended Data Figure 7 
 
Summary of MD simulations conducted of µOR.  
 
 
 
 
name action 
7-pet agonist 
acetylfentanyl agonist 
acetylmethadol agonist 
acrylfentanyl agonist 
ah-7921 agonist 
alfentanil agonist 
alimadol agonist 
3-allylfentanyl agonist 
allylnorpethidine agonist 
allylprodine agonist 
alphacetylmethadol agonist 
alphamethadol agonist 
alphamethylthiofentanyl agonist 
anileridine agonist 
azaprocin agonist 
azidomorphine agonist 
bdpc agonist 
benzethidine agonist 
betacetylmethadol agonist 
betahydroxyfentanyl agonist 
betahydroxythiofentanyl agonist 
betamethadol agonist 
bezitramide agonist 
brifentanil agonist 
bromadoline agonist 
butyrfentanyl agonist 
c-8813 agonist 
carfentanil agonist 
cebranopadol agonist 
chloromorphide agonist 
chloroxymorphamine agonist 
ciprefadol agonist 
clonitazene agonist 
dadle agonist 
damgo agonist 
dermorphin agonist 
desmethylprodine agonist 
desomorphine agonist 
dextromoramide agonist 
dextropropoxyphene agonist 
diampromide agonist 
difenoxin agonist 
dihydroetorphine agonist 
dihydromorphine agonist 
dimenoxadol agonist 
dimepheptanol agonist 
dimethylaminopivalophenone agonist 
dioxaphetyl_butyrate agonist 
diphenoxylate agonist 
dipipanone agonist 
dpi-3290 agonist 
eluxadoline agonist 
endomorphin agonist 
endomorphin-1 agonist 
endomorphin-2 agonist 
ethoheptazine agonist 
14-ethoxymetopon agonist 
etonitazene agonist 
etorphine agonist 
etoxeridine agonist 
fentanyl agonist 
4-fluorobutyrfentanyl agonist 
4-fluoropethidine agonist 
furanylfentanyl agonist 
furethidine agonist 
hemorphin-4 agonist 
heterocodeine agonist 
hydromorphinol agonist 
hydromorphone agonist 
hydroxypethidine agonist 
ibntxa agonist 
ic-26 agonist 
isomethadone agonist 
ketamine agonist 
ketobemidone agonist 
lefetamine agonist 
levacetylmethadol agonist 
levallorphan agonist 
levomethadone agonist 
levophenacylmorphan agonist 
levorphanol agonist 
lofentanil agonist 
loperamide agonist 
meprodine agonist 
metethoheptazine agonist 
methadone agonist 
metheptazine agonist 
4-methoxybutyrfentanyl agonist 
14-methoxydihydromorphinone agonist 
14-methoxymetopon agonist 
alpha-methylacetylfentanyl agonist 
3-methylbutyrfentanyl agonist 
n-methylcarfentanil agonist 
methyldesorphine agonist 
methyldihydromorphine agonist 
6-methylenedihydrodesoxymorphine agonist 
3-methylfentanyl agonist 
beta-methylfentanyl agonist 
methylketobemidone agonist 
3-methylthiofentanyl agonist 
metopon agonist 
mitragynine_pseudoindoxyl agonist 
6-monoacetylmorphine agonist 
morpheridine agonist 
morphine agonist 
morphine-6-glucuronide agonist 
morphinone agonist 
mr-2096 agonist 
mt-45 agonist 
noracymethadol agonist 
ocfentanil agonist 
ohmefentanyl agonist 
oliceridine agonist 
oxpheneridine agonist 
oxymorphazone agonist 
oxymorphol agonist 
oxymorphone agonist 
parafluorofentanyl agonist 
pentamorphone agonist 
pepap agonist 
pethidine agonist 
phenadoxone agonist 
phenampromide agonist 
phenaridine agonist 
phenazocine agonist 
pheneridine agonist 
n-phenethylnordesomorphine agonist 
n-phenethylnormorphine agonist 
phenomorphan agonist 
phenoperidine agonist 
4-phenylfentanyl agonist 
14-phenylpropoxymetopon agonist 
picenadol agonist 
piminodine agonist 
piritramide agonist 
prodilidine agonist 
prodine agonist 
proheptazine agonist 
properidine agonist 
propylketobemidone agonist 
prosidol agonist 
pzm21 agonist 
r-4066 agonist 
r-30490 agonist 
racemorphan agonist 
remifentanil agonist 
ro4-1539 agonist 
sc-17599 agonist 
semorphone agonist 
sufentanil agonist 
thienorphine agonist 
thiofentanyl agonist 
tilidine agonist 
trefentanil agonist 
trimeperidine agonist 
trimu_5 agonist 
u-47700 agonist 
u-77891 agonist 
viminol agonist 
6beta-naltrexol-d4 antagonist 
beta-chlornaltrexamine antagonist 
beta-funaltrexamine antagonist 
alvimopan antagonist 
at-076 antagonist 
axelopran antagonist 
bevenopran antagonist 
clocinnamox antagonist 
cyclofoxy antagonist 
cyprodime antagonist 
eptazocine antagonist 
ly-255582 antagonist 
methocinnamox antagonist 
methylnaltrexone antagonist 
methylsamidorphan antagonist 
nalmefene antagonist 
naloxazone antagonist 
naloxegol antagonist 
naloxol antagonist 
naloxonazine antagonist 
naloxone antagonist 
naltrexazone antagonist 
naltrexone antagonist 
oxilorphan antagonist 
quadazocine antagonist 
samidorphan antagonist 
 
 
Extended Data Table 1 
 
List of agonists and antagonists used to fit machine learned classifiers. All ligands and labels derived from 
Wikipedia (https://en.wikipedia.org/wiki/Template:Opioid_receptor_modulators), with some removed on advice by 
colleagues (cf. Acknowledgements section).  
 
 
a) 
Fentanyl analog ligands (test set): 
['acetylfentanyl', 'acrylfentanyl', '3-allylfentanyl', 'alphamethylthiofentanyl', 'azaprocin', 
'betahydroxyfentanyl', 'betahydroxythiofentanyl', 'butyrfentanyl', 'carfentanil', 'desmethylprodine', 
'diampromide', 'fentanyl', '4-fluorobutyrfentanyl', 'furanylfentanyl', 'lofentanil', '4-
methoxybutyrfentanyl', 'alpha-methylacetylfentanyl', '3-methylbutyrfentanyl', 'n-
methylcarfentanil', '3-methylfentanyl', 'beta-methylfentanyl', '3-methylthiofentanyl', 'ocfentanil', 
'ohmefentanyl', 'parafluorofentanyl', 'pepap', 'phenampromide', 'phenaridine', '4-phenylfentanyl', 
'prodilidine', 'prodine', 'proheptazine', 'prosidol', 'r-30490', 'remifentanil', 'sufentanil', 
'thiofentanyl', 'trimeperidine', 'u-47700'] 
 
Non-fentanyl-analog agonists (train set): 
['7-pet', 'alimadol', 'alphamethadol', 'azidomorphine', 'bdpc', 'betamethadol', 'c-8813', 
'cebranopadol', 'chloromorphide', 'chloroxymorphamine', 'ciprefadol', 'clonitazene', 'dadle', 
'damgo', 'desomorphine', 'dihydroetorphine', 'dihydromorphine', 'dimenoxadol', 'dimepheptanol', 
'dimethylaminopivalophenone', 'eluxadoline', 'endomorphin', 'endomorphin-1', '14-
ethoxymetopon', 'etonitazene', 'etorphine', 'hemorphin-4', 'heterocodeine', 'hydromorphinol', 
'hydromorphone', 'ibntxa', 'ketamine', 'lefetamine', 'levophenacylmorphan', 'levorphanol', '14-
methoxydihydromorphinone', '14-methoxymetopon', 'methyldesorphine', 
'methyldihydromorphine', '6-methylenedihydrodesoxymorphine', 'metopon', 
'mitragynine_pseudoindoxyl', '6-monoacetylmorphine', 'morphine', 'morphine-6-glucuronide', 
'morphinone', 'mr-2096', 'oliceridine', 'oxymorphazone', 'oxymorphol', 'oxymorphone', 
'pentamorphone', 'phenazocine', 'n-phenethylnordesomorphine', 'n-phenethylnormorphine', 
'phenomorphan', '14-phenylpropoxymetopon', 'picenadol', 'pzm21', 'racemorphan', 'ro4-1539', 'sc-
17599', 'semorphone', 'thienorphine', 'tilidine', 'trimu_5', 'viminol'] 
 
Antagonists:  
['levallorphan', '6beta-naltrexol-d4', 'beta-chlornaltrexamine', 'beta-funaltrexamine', 'alvimopan', 
'at-076', 'axelopran', 'bevenopran', 'clocinnamox', 'cyclofoxy', 'cyprodime', 'eptazocine', 'ly-
255582', 'methocinnamox', 'methylnaltrexone', 'methylsamidorphan', 'nalmefene', 'naloxazone', 
'naloxegol', 'naloxol', 'naloxonazine', 'naloxone', 'naltrexazone', 'naltrexone', 'oxilorphan', 
'quadazocine', 'samidorphan'] 
 
b) 
 
Methadone analog ligands (test set): 
['acetylmethadol', 'alphacetylmethadol', 'alphamethadol', 'betacetylmethadol', 'betamethadol', 
'dipipanone', 'ic-26', 'isomethadone', 'ketobemidone', 'levacetylmethadol', 'levomethadone', 
'methadone', 'methylketobemidone', 'noracymethadol', 'phenadoxone', 'propylketobemidone', 'r-
4066'] 
 
Non-methadone analogs (train set): 
['7-pet', 'alimadol', 'azidomorphine', 'bdpc', 'c-8813', 'cebranopadol', 'chloromorphide', 
'chloroxymorphamine', 'ciprefadol', 'clonitazene', 'dadle', 'damgo', 'desomorphine', 
'dihydroetorphine', 'dihydromorphine', 'dimenoxadol', 'dimepheptanol', 
'dimethylaminopivalophenone', 'eluxadoline', 'endomorphin', 'endomorphin-1', '14-
ethoxymetopon', 'etonitazene', 'etorphine', 'hemorphin-4', 'heterocodeine', 'hydromorphinol', 
'hydromorphone', 'ibntxa', 'ketamine', 'lefetamine', 'levophenacylmorphan', 'levorphanol', '14-
methoxydihydromorphinone', '14-methoxymetopon', 'methyldesorphine', 
'methyldihydromorphine', '6-methylenedihydrodesoxymorphine', 'metopon', 
'mitragynine_pseudoindoxyl', '6-monoacetylmorphine', 'morphine', 'morphine-6-glucuronide', 
'morphinone', 'mr-2096', 'oliceridine', 'oxymorphazone', 'oxymorphol', 'oxymorphone', 
'pentamorphone', 'phenazocine', 'n-phenethylnordesomorphine', 'n-phenethylnormorphine', 
'phenomorphan', '14-phenylpropoxymetopon', 'picenadol', 'pzm21', 'racemorphan', 'ro4-1539', 'sc-
17599', 'semorphone', 'thienorphine', 'tilidine', 'trimu_5', 'viminol'] 
 
Antagonists: 
['levallorphan', '6beta-naltrexol-d4', 'beta-chlornaltrexamine', 'beta-funaltrexamine', 'alvimopan', 
'at-076', 'axelopran', 'bevenopran', 'clocinnamox', 'cyclofoxy', 'cyprodime', 'eptazocine', 'ly-
255582', 'methocinnamox', 'methylnaltrexone', 'methylsamidorphan', 'nalmefene', 'naloxazone', 
'naloxegol', 'naloxol', 'naloxonazine', 'naloxone', 'naltrexazone', 'naltrexone', 'oxilorphan', 
'quadazocine', 'samidorphan'] 
 
Extended Data Table 2 
 
a) 
 
A scaffold split was defined in which (1) agonist ligands with a Tanimoto score of ≤0.5 
compared to fentanyl were placed in a train set, (2) agonist ligands with a Tanimoto score of 
≥0.7 compared to fentanyl were placed in a test set, and (3) antagonists were randomly 
distributed between the train and test sets.  
 
b) A scaffold split was defined in which (1) agonist ligands with a Tanimoto score of ≤0.5 
compared to methadone were placed in a train set, (2) agonist ligands with a Tanimoto score of 
≥0.7 compared to methadone were placed in a test set, and (3) antagonists were randomly 
distributed between the train and test sets.  
 
 
a)  
 Inactive Crystal    0.063488 
 State 14            0.033463 
 State 3             0.031175 
 State 17            0.029950 
 State 10            0.029853 
 State 23            0.025154 
 State 5             0.024361 
 State 16            0.023912 
 State 21            0.023884 
 State 4             0.021384 
 State 22            0.020618 
 State 0             0.019934 
 State 13            0.019720 
 State 18            0.017975 
 State 7             0.017955 
 State 24            0.017434 
 State 11            0.017295 
 State 9             0.016170 
 State 8             0.015486 
 State 15            0.015193 
 State 19            0.013673 
 Active Crystal      0.013580 
 State 12            0.013346 
 State 6             0.012534 
 State 2             0.012306 
 State 1             0.012289 
 State 20            0.011230 
 
b) 
 
 Inactive Crystal    0.057546 
 State 18            0.051126 
 State 2             0.050497 
 State 14            0.045177 
 State 1             0.043236 
 Active Crystal      0.040393 
 State 20            0.039999 
 State 3             0.037063 
 State 24            0.035946 
 State 19            0.035883 
 State 17            0.035723 
 State 5             0.035547 
 State 22            0.034922 
 State 16            0.034121 
 State 0             0.034035 
 State 21            0.033999 
 State 4             0.033884 
 State 6             0.033837 
 State 13            0.033381 
 State 10            0.032723 
 State 11            0.032537 
 State 23            0.032248 
 State 12            0.032069 
 State 9             0.031896 
 State 15            0.031409 
 State 8             0.030558 
 State 7             0.030245 
 
 
Extended Data Table 3 
  
Random Forest average Gini impurity reduction (“importance”) of each feature (MD State, Crystal Structure) for a) 
distinguishing between opioid agonists and antagonists and b) distinguishing between binders and non-binders from 
µOR. 
 
 
 
 
Extended Data Table 4 
 
Docking to both MD states and crystal structures statistically significantly improves ability over crystals alone to 
distinguish µOR binders from non-binders. Table shows median ROC Area Under the Curve (AUC) performance 
over the validation set over 1,000 train-valid splits for different split and model types. Differences between crystal 
lone and crystal + MD structures methods are considered statistically significant if the lower bound of a 99% Wilson 
scoring confidence interval (CI) is greater than 0.5. Note that, for each dataset, incorporating MD-derived structures 
in addition to the crystal structures confers a statistically significant improvement in ability to distinguish binders 
from non-binder as measured by AUC. Notably, when fentanyl (or methadone) analogs are removed from the 
training set, models remain able to distinguish fentanyl (or methadone) derivative agonists from random sets of 
antagonists. This indicates that models fit in this way have the capacity to discover new opioid agonist scaffolds in 
addition to derivatives of existing ones.  
 
 
 
 
Dataset Cross validation split type
AUC (Crystals 
alone)
AUC (Crystal + MD 
structures) Wilson 99% CI
Wikipedia 
Agonists/Antagonists Random 0.72 0.86 (0.82, 0.88)
Wikipedia 
Agonists/Antagonists Methadone 0.84 0.99 (0.82, 0.88)
Wikipedia 
Agonists/Antagonists Fentanyl 0.77 0.93 (0.98, 1.0)
Expert curated 
dataset Random 0.73 0.85 (0.67, 0.75)
Expert curated 
dataset Methadone 0.89 0.94 (0.51, 0.59)
Expert curated 
dataset Fentanyl 0.81 0.91 (0.88, 0.93)
 
 
Extended Data Table 5 
 
Docking to both MD states and crystal structures statistically significantly improves ability over crystals alone to 
distinguish µOR binders from non-binders. Table shows median ROC Area Under the Curve (AUC) performance 
over the validation set over 1,000 train-valid splits for different split and model types. Differences between crystal 
lone and crystal + MD structures methods are considered statistically significant if the lower bound of a 99% Wilson 
scoring confidence interval (CI) is greater than 0.5. Note that, for each dataset, incorporating MD-derived structures 
in addition to the crystal structures confers a statistically significant improvement in ability to distinguish binders 
from non-binder as measured by AUC. Notably, when molecules with similar scaffolds (as measured by a Tanimoto 
similarity score of > 0.7) are removed from the training data, models remain able to distinguish binders from non-
binders. This indicates that models fit in this way have the capacity to discover new opioid scaffolds in addition to 
derivatives of existing ones.  
 
Datasets consist of compounds with experimentally known values of binding affinity to µOR according to Chembl, 
Wikipedia, and other publicly available sources (full list of ligands in this dataset available in supplemental files). 
Datasets termed “Measured Ki” include only those compounds with a real-numbered Ki value listed in Chembl; 
datasets termed “All” also include compounds that have no listed Ki but are termed “Not Active” by Chembl. 
Therefore, “Measured Ki” datasets are subsets of the “All” series of datasets. Binders are considered to be 
compounds with a pIC50 greater than some cutoff (listed in the “Dataset” table) and non-binders with a pIC50 lower 
than that same cutoff. For example, “All, pIC50 cutoff = 7.0” indicates a dataset wherein (a) both ligands with a 
measurable pIC50 < 7.0 and those listed as “Not Active” in Chembl are considered non-binders, and (b) both ligands 
with a measurable pIC50 ≥ 7.0 and other known agonists and antagonists from Wikipedia are considered to be 
binders. 
 
 
 
FMP # Supplier Catalogue no. Molecular     Weight Structure 
1 ChemBridge Corp 5315117 261.409 
 
Dataset Split AUC (Crystals alone) AUC (Crystal + MD structures) Wilson 99% CI
Measured pIC50, cutoff = 6.0 Random 0.59 0.64 (0.76, 0.82)
Measured pIC50, cutoff = 7.0 Random 0.59 0.71 (0.99, 1.0)
Measured pIC50 cutoff = 8.0 Random 0.58 0.74 (0.99, 1.0)
All, pIC50 cutoff = 5.3 Random 0.78 0.87 (0.99, 1.0)
All, pIC50 cutoff = 6.0 Random 0.73 0.82 (0.99, 1.0)
All, pIC50 cutoff = 7.0 Random 0.67 0.78 (0.99, 1.0)
All, pIC50 cutoff = 8.0 Random 0.65 0.79 (0.99, 1.0)
All, pIC50 cutoff = 5.3 Scaffold 0.77 0.81 (0.73, 0.80)
All, pIC50 cutoff = 6.0 Scaffold 0.78 0.83 (0.73, 0.8)
All, pIC50 cutoff = 7.0 Scaffold 0.66 0.79 (0.86, 0.91)
All, pIC50 cutoff = 8.0 Scaffold 0.64 0.78 (0.85, 0.9)
2 Vitas-M Laboratory STK246443 220.272 
 
3 ChemBridge Corp 5421855 298.471 
 
4 ChemBridge Corp 5359784 286.419 
 
5 ChemDiv, Inc. K416-0034 331.45 
 
6 ChemDiv, Inc. 6030-4029 277.408 
 
7 ChemDiv, Inc. D171-0103 284.403 
 
8 ChemDiv, Inc. K808-9296 317.388 
 
9 ChemDiv, Inc. C296-0706 379.43 
 
10 ChemDiv, Inc. C656-0381 347.353 
 
11 InterBioScreen Ltd. STOCK1S-36272 255.4 
 
12 Life Chemicals Inc. F5959-0041 249.33 
13 Life Chemicals Inc. F6350-0021 228.31 
 
14 MayBridge, Ltd. S14427 325.324 
 
15 MayBridge, Ltd. CC52213 207.273 
 
16 Specs AG-644/14117620 286.419 
 
17 Specs AF-399/41900457 282.77 
 
18 Specs AK-968/13031275 335.23 
 
19 Specs AG-690/11549877 265.353 
 
20 Specs AF-399/41875794 291.435 
 
21 Specs AG-664/15584112 290.451 
 
22 Specs AG-690/11764068 308.422 
 
23 Vitas-M Laboratory STK768975 354.47 
 
24 Vitas-M Laboratory STK825555 408.28 
 
25 Vitas-M Laboratory STK705512 390.399 
 
26 Vitas-M Laboratory STL181788 309.453 
 
27 Vitas-M Laboratory STK123054 253.301 
 
28 Vitas-M Laboratory STK386756 343.28 
 
29 Vitas-M Laboratory STK766152 285.387 
 
30 ChemBridge Corp 5316199 263.381 
 
31 ChemBridge Corp 5455149 225 
 
32 ChemBridge Corp 5410648 280 
 
 
Extended Data Table 6 
 
List of all 32 purchased compounds that were experimentally tested for binding.  
 
	
 
 
 
 
 
	
Extended Table Data 7. Receptor binding of FMP4 and structurally similar analogs 
	
a	Competition	studies	were	performed	with	the	indicated	compounds	against	125I-IBNtxA	(0.1	
nM)	in	membranes	from	CHO	cells	stably	expressing	the	indicated	cloned	mouse	opioid	
receptors.	Results	are	presented	as	nM	±	SEM	from	three	independent	experiments	performed	
in	triplicate.	b	Values	from	the	literature.8		
	
 
  
FMP# Structure MW MOR-1 KOR-1 DOR-1
1 261.409 841.4 ±241.9 7386 ±2376 17874 ±7615
4 286.419 3217 ±153 2503 ±523 8143 ±1398
6 277.408 >30µM 6941 ±1970 >30µM
16 286.419 1748 ±492 4918 ±2235 9058 ±566
21 290.451 >30µM 5503 ±4194 >30µM
30 263.381 11315 ±2262 6009 ±2163 12761 ±856
DAMGO 3.3	±	0.43 b
U50,488h 0.73	±	0.32 b
DPDPE 1.39	±	0.67 b
Binding	Data	-	K i	(nM)a
